Inhibition of PKCα activation in human bone and soft tissue sarcoma cells by the selective PKC inhibitor PKC412

Anticancer Research

Volumn 28, Issue 2 A, 2008, Pages 825-832

  Kawamoto, Teruya ^a   Akisue, Toshihiro ^a   Kishimoto, Kenta ^a   Hara, Hitomi ^a   Imabori, Masaya ^a   Fujimoto, Takuya ^a   Kurosaka, Masahiro ^a   Hitora, Toshiaki ^b   Kawaguchi, Yoji ^b   Yamamoto, Tetsuji ^b  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KAGAWA UNIVERSITY   (Japan)

Author keywords

Malignant fibrous histiocytoma (MFH); Molecular targeting therapy; Osteosarcoma; PKC ; PKC412; Sarcoma

Indexed keywords

MIDOSTAURIN; PROTEIN KINASE C ALPHA; DRUG DERIVATIVE; PROTEIN KINASE C; PROTEIN KINASE INHIBITOR; STAUROSPORINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; DRUG EFFECT; DRUG POTENCY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOCYTOCHEMISTRY; OSTEOSARCOMA; PRIORITY JOURNAL; SOFT TISSUE SARCOMA; TIME; WESTERN BLOTTING; BONE TUMOR; DRUG ANTAGONISM; ENZYMOLOGY; IMMUNOHISTOCHEMISTRY; PATHOLOGY; SARCOMA; TUMOR CELL LINE;

BONE NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; ENZYME ACTIVATION; HUMANS; IMMUNOHISTOCHEMISTRY; PROTEIN KINASE C; PROTEIN KINASE INHIBITORS; SARCOMA; STAUROSPORINE;

EID: 42549105463     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Papai Z, Bodoky G, Szanto J, Poller I, Rahoty P, Eckhardt S, Lang I and Szendroi M: The efficacy of a combination of etoposide, ifosfamide, and cisplatin in the treatment of patients with soft tissue sarcoma. Cancer 89: 177-180, 2000.
2. Spira AI and Ettinger DS: The use of chemotherapy in soft-tissue sarcomas. Oncologist 7: 348-359, 2002.
3. McGary EC, Weber K, Mills L, Doucet M, Lewis V, Lev DC, Fidler IJ and Bar-Eli M: Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571. Clin Cancer Res 8: 3584-3591, 2002.
4. Abdiu A, Walz TM, Nishikawa BK, Wingren S, Larsson SE and Wasteson A: Human malignant fibrous histiocytomas in vitro: growth characteristics and their association with expression of mRNA for platelet-derived growth factor, transforming growth factor-alpha and their receptors. Eur J Cancer 34: 2094-2100, 1998.
5. Yamamoto T, Akisue T, Marui T, Fujita I, Matsumoto K, Kawamoto T, Hitora T, Nakatani T, Nagira K and Kurosaka M: Immunohistochemical analysis of platelet-derived growth factor and its receptors in soft tissue malignant fibrous histiocytoma. Anticancer Res 23: 4325-4328, 2003.
6. Nakatani T, Marui T, Yamamoto T, Hitora T, Akisue T, Kawamoto T, Nagira K, Fujita I, Matsumoto K, Yoshiya S and Kurosaka M: Expression of stem cell factor and c-kit in human malignant fibrous histiocytoma cell line (TNMY1). Anticancer Res 23: 2329-2333, 2003.
7. Hitora T, Yamamoto T, Akisue T, Marui T, Nakatani T, Kawamoto T, Nagira K, Yoshiya S and Kurosaka M: Establishment and characterization of a KIT-positive and stem cell factor-producing cell line, KTHOS, derived from human osteosarcoma. Pathol Int 55: 41-47, 2005.
8. Hara H, Akisue T, Fujimoto T, Imabori M, Kawamoto T, Kuroda R, Fujioka H, Yamamoto T, Doita M and Kurosaka M; Expression of VEGF and its receptors and angiogenesis in bone and soft tissue tumors. Anticancer Res 26: 4307-4311, 2006.
9. Hibi K, Takahashi T, Sekido Y, Ueda R, Hida T, Ariyoshi Y, Takagi H and Takahashi T: Coexpression of the stem cell factor and the c-kit genes in small-cell lung cancer. Oncogene 6: 2291-2296, 1991.
10. Bauer S, Corless CL, Heinrich MC, Dirsch O, Antoch G, Kanja J, Seeber S and Schutte J: Response to imatinib mesylate of a gastrointestinal stromal tumor with very low expression of KIT. Cancer Chemother Pharmacol 51: 261-265, 2003.
11. Hwang RF, Yokoi K, Bucana CD, Tsan R, Killion JJ, Evans DB and Fidler IJ: Inhibition of platelet-derived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model. Clin Cancer Res 9: 6534-6544, 2003.
12. Koivunen J, Aaltonen V and Peltonen J: Protein kinase C (PKC) family in cancer progression. Cancer Lett 235: 1-10, 2006.
13. Hanania N, Lezenes JR and Castagna M: Tumorigenicity-associated expression of protein kinase C isoforms in rhabdomyosarcoma-derived cells. FEBS Lett 303: 15-18, 1992.
14. Geng WD, Boskovic G, Fultz ME, Li C, Niles RM, Ohno S and Wright GL: Regulation of expression and activity of four PKC isozymes in confluent and mechanically stimulated UMR-108 osteoblastic cells. J Cell Physiol 189: 216-228, 2001.
15. Keller HU, Hunziker IP, Sordat B, Niggli V and Sroka J: Protein kinase C isoforms involved in regulation of cell shape and locomotion of human fibrosarcoma HT1080 cells. Int J Cancer 88: 195-203, 2000.
16. Carey I, Williams CL, Ways DK and Noti JD: Overexpression of protein kinase C-alpha in MCF-7 breast cancer cells results in differential regulation and expression of alphavbeta3 and alphavbeta5. Int J Oncol 15: 127-136, 1999.
17. Stewart JR and O'Brian CA: Protein kinase C-alpha mediates epidermal growth factor receptor transactivation in human prostate cancer cells. Mol Cancer Ther 4: 726-732, 2005.
18. Fabbro D, Buchdunger E, Wood J, Mestan J, Hofmann F, Ferrari S, Mett H, O'Reilly T and Meyer T: Inhibitors of protein kinases: CGP 41251, a protein kinase inhibitor with potential as an anticancer agent. Pharmacol Ther 82: 293-301, 1999.
19. Fabbro D, Ruetz S, Bodis S, Pruschy M, Csermak K, Man A, Campochiaro P, Wood J, O'Reilly T and Meyer T: PKC412-a protein kinase inhibitor with a broad therapeutic potential. Anticancer Drug Des 15: 17-28, 2000.
20. Hemstrom TH, Joseph B, Schulte G, Lewensohn R and Zhivotovsky B: PKC 412 sensitizes U1810 non-small cell lung cancer cells to DNA damage. Exp Cell Res 305: 200-213, 2005.
21. Ikegami Y, Yano S and Nakao K: Antitumor effect of CGP41251, a new selective protein kinase C inhibitor, on human non-small cell lung cancer cells. Jpn J Pharmacol 70: 65-72, 1996.
22. Kim M, Park IY, Lim J, Kim Y, Han KT, Chung WH and Han K: Antitumor and normal cell protective effect of PKC412 in the athymic mouse model of ovarian cancer. Ann Clin Lab Sci 36: 455-460, 2006.
23. Sharkey J, Khong T and Spencer A: PKC412 demonstrates JNK-dependent activity against human multiple myeloma cells. Blood 109: 1712-1719, 2007.
24. Shih A, Zhang S, Cao HJ, Boswell S, Wu YH, Tang HY, Lennartz MR, Davis FB, Davis PJ and Lin HY: Inhibitory effect of epidermal growth factor on resveratrol-induced apoptosis in prostate cancer cells is mediated by protein kinase C-alpha. Mol Cancer Ther 3: 1355-1364, 2004.
25. Nakamura K, Yoshikawa N, Yamaguchi Y, Kagota S, Shinozuka K and Kunitomo M: Effect of PKC412, an inhibitor of protein kinase C, on spontaneous metastatic model mice. Anticancer Res 23: 1395-1399, 2003.
26. Nakatani T, Marui T, Yamamoto T, Kurosaka M, Akisue T and Matsumoto K: Establishment and characterization of cell line TNMY1 derived from human malignant fibrous histiocytoma. Pathol Int 51: 595-602, 2001.
27. Fang Z, Mukai H, Nomura K, Shinomiya K, Matsumoto S, Kawaguchi N, Kitagawa T and Kanda H: Establishment and characterization of a cell line from a malignant fibrous histiocytoma of bone developing in a patient with multiple fibrous dysplasia. J Cancer Res Clin Oncol 128: 45-49, 2002.
28. Kiyozuka Y, Nakagawa H, Uemura Y, Senzaki H, Yamamoto A, Noguchi T, Mizuta H, Nakanishi K, Nakano S and Tsubura A: Novel cell lines established from a human myxoid malignant fibrous histiocytoma arising in the uterus. Cancer Genet Cytogenet 127: 7-15, 2001.
29. Sjoblom T, Shimizu A, O'Brien KP, Pietras K, Dal Cin P, Buchdunger E, Dumanski JP, Ostman A and Heldin CH; Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Cancer Res 61: 5778-5783, 2001.
30. Kawamoto T, Akisue T, Marui T, Nakatani T, Hitora T, Fujita I, Kurosaka M and Yamamoto T: Inhibitory effect of STI571 on cell proliferation of human malignant fibrous histiocytoma cell lines. Anticancer Res 24: 2675-2679, 2004.
31. Irsan I, Akisue T, Hara H, Fujimoto T, Imabori M, Doita M, Kuroda R, Fujioka H, Kawamoto T, Yamamoto T and Kurosaka M: Imatinib mesylate inhibits tumorigenicity of malignant fibrous histiocytoma cells in vivo. Anticancer Res 27: 423-429, 2007.
32. Dlugosz AA, Cheng C, Williams EK, Dharia AG, Denning MF and Yuspa SH: Alterations in murine keratinocyte differentiation induced by activated rasHa genes are mediated by protein kinase C-alpha. Cancer Res 54: 6413-6420, 1994.
33. Zhan M, Yu D, Liu J, Glazer RI, Hannay J and Pollock RE: Transcriptional repression of protein kinase Calpha via Sp1 by wild-type p53 is involved in inhibition of multidrug resistance 1 P-glycoprotein phosphorylation. J Biol Chem 280: 4825-4833, 2005.
34. Gill PK, Gescher A and Gant TW: Regulation of MDR1 promoter activity in human breast carcinoma cells by protein kinase C isozymes alpha and theta. Eur J Biochem 268: 4151-4157, 2001.
35. Hofmann J; Modulation of protein kinase C in antitumor treatment. Rev Physiol Biochem Pharmacol 142: 1-96, 2001.
36. Propper DJ, McDonald AC, Man A, Thavasu P, Balkwill F, Braybrooke JP, Caponigro F, Graf P, Dutreix C, Blackie R, Kaye SB, Ganesan TS, Talbot DC, Harris AL and Twelves C: Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. J Clin Oncol 19: 1485-1492, 2001.
37. Eder JP Jr, Garcia-Carbonero R, Clark JW, Supko JG, Puchalski TA, Ryan DP, Deluca P, Wozniak A, Campbell A, Rothermel J and LoRusso P: A phase I trial of daily oral 4′-N-benzoyl-staurosporine in combination with protracted continuous infusion 5-fluorouracil in patients with advanced solid malignancies. Invest New Drugs 22: 139-150, 2004.
38. Monnerat C, Henriksson R, Le Chevalier T, Novello S, Berthaud P, Faivre S and Raymond E: Phase I study of PKC412 (N-benzoyl-staurosporine), a novel oral protein kinase C inhibitor, combined with gemcitabine and cisplatin in patients with non-small-cell lung cancer. Ann Oncol 15: 316-323, 2004.